NasdaqGS - Nasdaq Real Time Price USD

Innoviva, Inc. (INVA)

14.99

-0.17

(-1.12%)

At close: April 25 at 4:00 PM EDT

14.99

0.00

(0.00%)

After hours: April 25 at 5:31 PM EDT

Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

WALTHAM, Mass., April 24, 2024--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced that positive results from the Phase 3 oral zoliflodacin trial will be highlighted in an oral presentation given by the Global Antibiotic Research & Development Partnership (GARDP) at the European Society of Clinical Microbiology and Infectious Disease Global Congress (ESCMID Global 2024) taking place April 27-30, 2024, in Barcelona, Spain. Zoliflodacin is a first

Business Wire yesterday

INVA
-1.12%
Should Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

It is hard to get excited after looking at Innoviva's (NASDAQ:INVA) recent performance, when its stock has declined 10...

Simply Wall St. 3 days ago

INVA
-1.12%
Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a secured credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"), Armata's largest shareholder. The gross proceeds to be received by the C

PR Newswire last month

INVA
-1.12%
ARMP
Innoviva Inc (INVA) Reports Growth Amidst Challenges in Q4 and Full Year 2023 Financial Results

Company Sees 35% Year-Over-Year Growth in Q4 Product Revenues

GuruFocus.com last month

INVA
-1.12%
GSK
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif., February 29, 2024--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the fourth quarter and full year ended December 31, 2023 and highlighted select corporate achievements.

Business Wire last month

INVA
-1.12%
Jim Simons Bolsters Position in Innoviva Inc with Recent Acquisition

Overview of the Recent Portfolio Addition Renaissance Technologies, led by Jim Simons (Trades, Portfolio), has recently expanded its investment portfolio with the addition of 4,144,447 shares in Innoviva Inc (NASDAQ:INVA). The transaction, which took place on December 29, 2023, reflects a 3.63% increase from the previous holding, marking a significant vote of confidence in the biopharmaceutical company. With a trade price of $16.04 per share, the firm has demonstrated a strategic move to capitalize on Innoviva's market potential.

GuruFocus.com 2 months ago

INVA
-1.12%
If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names

The great advances and improvements in the treatment of diseases and the effectiveness of these medicines are undoubtedly due to technological progress and how biotech companies take advantage of it for their growth and development. Without the work of these companies, we would still be using very old and ineffective medicines. This new year brings with it very good opportunities to invest in companies in this sector. Here are these top biotech stocks to consider adding to your portfolio. Let’s

InvestorPlace 3 months ago

BMRN

INVA
-1.12%
IQV
Innoviva's (NASDAQ:INVA) investors will be pleased with their 29% return over the last three years

One simple way to benefit from the stock market is to buy an index fund. But if you pick the right individual stocks...

Simply Wall St. 3 months ago

INVA
-1.12%
Insider Sell Alert: Marianne Zhen Offloads Shares of Innoviva Inc

In the realm of stock market movements, insider trading activity is often a significant indicator that investors keep a close eye on.

GuruFocus.com 5 months ago

INVA
-1.12%
Innoviva, Inc. (NASDAQ:INVA) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?

Most readers would already know that Innoviva's (NASDAQ:INVA) stock increased by 2.5% over the past month. However, the...

Simply Wall St. 5 months ago

INVA
-1.12%
Innoviva Inc (INVA) Reports Q3 2023 Financial Results: Net Income Drops to $82.0 Million

Despite a decrease in net income, the company shows promise with the launch of new therapy and positive Phase 3 data

GuruFocus.com 5 months ago

INVA
-1.12%
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

BURLINGAME, Calif., November 01, 2023--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the third quarter ended September 30, 2023, highlighted select corporate achievements and provided an overview of its key business initiatives.

Business Wire 5 months ago

INVA
-1.12%
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

GENEVA & WALTHAM, Mass., November 01, 2023--The Global Antibiotic Research & Development Partnership (GARDP), in collaboration with Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), announced today that zoliflodacin, a first-in-class antibiotic, met its primary endpoint in an unprecedented global pivotal Phase 3 clinical trial. Study investigators found that oral zoliflodacin demonstrated statistical non-inferiority of microbiological cure at the urogenital site whe

Business Wire 5 months ago

INVA
-1.12%
Calculating The Intrinsic Value Of Innoviva, Inc. (NASDAQ:INVA)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Innoviva fair value estimate is US$11.69 Innoviva's US$13.37...

Simply Wall St. 6 months ago

INVA
-1.12%
Innoviva to Participate in the Cantor Global Healthcare Conference

BURLINGAME, Calif., September 19, 2023--Innoviva, Inc. (Nasdaq: INVA) ("Innoviva"), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Cantor Global Healthcare Conference in New York, NY on Wednesday, September 27, 2023 at 1:50 p.m. Eastern Time.

Business Wire 7 months ago

INVA
-1.12%
XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults

WALTHAM, Mass., September 18, 2023--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that XACDURO® (sulbactam for injection; durlobactam for injection) is now available in the United States for patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter).

Business Wire 7 months ago

INVA
-1.12%
Innoviva Appoints Stephen Basso as Chief Financial Officer

BURLINGAME, Calif., August 25, 2023--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" and "the Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced the appointment of Stephen Basso as its Chief Financial Officer, effective August 21, 2023.

Business Wire 7 months ago

INVA
-1.12%
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

BURLINGAME, Calif., August 02, 2023--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the second quarter ended June 30, 2023, highlighted select corporate achievements and provided an overview of its key business initiatives.

Business Wire 8 months ago

INVA
-1.12%
Investors in Innoviva (NASDAQ:INVA) have unfortunately lost 11% over the last year

Investors can approximate the average market return by buying an index fund. When you buy individual stocks, you can...

Simply Wall St. 8 months ago

INVA
-1.12%
Why These 7 Stocks Are the Best Ways to Play Biotech Right Now

Best biotech stocks represents a concept that, no matter what, the market cycle fundamentally delivers relevance. Now, let me back up by stating that no individual company offers a guarantee of success to investors. You must conduct your own due diligence. However, as a narrative, the biotechnology industry stands at the forefront of humanitarian innovation. The space has never been more important than it is right now. From the strictly financial view of investing in biotech stocks, the underlyi

InvestorPlace 9 months ago

REGN

VYGR
-1.98%
INVA
-1.12%

Performance Overview

Return	INVA	S&P 500
YTD	-6.55%	+5.84%
1-Year	+27.03%	+22.03%
3-Year	+28.12%	+20.77%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Innoviva, Inc. (INVA)

Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Should Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

Innoviva Inc (INVA) Reports Growth Amidst Challenges in Q4 and Full Year 2023 Financial Results

Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress

Jim Simons Bolsters Position in Innoviva Inc with Recent Acquisition

If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names

Innoviva's (NASDAQ:INVA) investors will be pleased with their 29% return over the last three years

Insider Sell Alert: Marianne Zhen Offloads Shares of Innoviva Inc

Innoviva, Inc. (NASDAQ:INVA) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?

Innoviva Inc (INVA) Reports Q3 2023 Financial Results: Net Income Drops to $82.0 Million

Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

Calculating The Intrinsic Value Of Innoviva, Inc. (NASDAQ:INVA)

Innoviva to Participate in the Cantor Global Healthcare Conference

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults

Innoviva Appoints Stephen Basso as Chief Financial Officer

Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Investors in Innoviva (NASDAQ:INVA) have unfortunately lost 11% over the last year

Why These 7 Stocks Are the Best Ways to Play Biotech Right Now

Performance Overview